The insider sales are too small to warrant a trading response. Monitor for any larger open-market sales or changes in 10b5-1 plans.
KRYS drugs
KRYS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $301.76entry
- T+1 · 5mo ago +2.65%α +2.94% · $309.75
- T+5 · 5mo ago +7.62%α +5.51% · $324.75
- T+20 · 4mo ago +24.16%α +22.53% · $374.68
- T+60 · 3mo ago +20.57%α +17.52% · $363.84
Price Chart
How similar events traded
Executive Summary
President and CEO Krishnan Krish S and President of R&D Krishnan Suma each sold 320 shares of Krystal Biotech on June 4, 2026, for a combined $192K. The sales are tiny relative to the $9.1B market cap (0.002%), are identical in size and price, and likely reflect routine tax-related or 10b5-1 plan activity rather than a bearish signal. The cluster is not material enough to change the fundamental outlook.
Key Financial Metrics
Key Facts
- Two insiders (CEO and President of R&D) each sold 320 shares at $300.75 on June 4, 2026.
- Total sale value is $192K, representing ~0.002% of the $9.1B market cap.
- Identical share counts and price suggest coordinated or plan-driven sales, not opportunistic selling.
- No open-market purchases in the cluster; no other material insider activity in the prior 30 days.
Financial Impact
Trivial, $192K in sales vs. $9.1B market cap (0.002%). No material financial impact.
Risk Factors
- Insider sales could increase if management is diversifying ahead of a catalyst event (e.g., pipeline readout).
- No purchases in the cluster, lack of insider buying may indicate management sees limited near-term upside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KRYS-1780699267801 |
Track record
18 reports on KRYS
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
- Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
- Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers